BCRX:NSD-BioCryst Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.59

Change

0.00 (0.00)%

Market Cap

USD 2.09B

Volume

3.61M

Analyst Target

USD 8.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

N/A

USD 13.60B
NBIX Neurocrine Biosciences Inc

N/A

USD 11.63B
VTRS Viatris Inc

N/A

USD 9.73B
LNTH Lantheus Holdings Inc

N/A

USD 7.11B
ALKS Alkermes Plc

N/A

USD 4.74B
ALVO Alvotech

N/A

USD 2.92B
HCM HUTCHMED DRC

N/A

USD 2.57B
KNSA Kiniksa Pharmaceuticals Ltd

N/A

USD 1.92B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.80B
EVO Evotec SE ADR

N/A

USD 1.68B

ETFs Containing BCRX

IDNA iShares Genomics Immunolo.. 3.29 % 0.00 %

N/A

USD 0.10B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.22 % 0.00 %

N/A

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.69 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.82% 83% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.82% 83% B 92% A
Trailing 12 Months  
Capital Gain 72.76% 88% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.76% 88% B+ 92% A
Trailing 5 Years  
Capital Gain 94.31% 89% A- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.31% 89% A- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 29.82% 69% C- 83% B
Dividend Return 29.82% 69% C- 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.15% 46% F 19% F
Risk Adjusted Return 30.07% 77% C+ 65% D
Market Capitalization 2.09B 90% A- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.